KRAS and neoplasm: Here, the average methylation of the tumor-free control (69.6%; n = 3) is higher, but without reaching significance due to low numbers, than the averages of female (36.7%; n = 18) and male (37.7%; n = 21) tumor samples as well as wildtype (37.7%; n = 23) and EGFR/KRAS mutated tumor samples (41.6%; n = 16).